Treatment Subgroups (Male) Treatment Subgroups (Female)   Week AML HCZ AML HCZ Gender Effect 0 236.20 ± 4.55 237.10 ± 2.85 233.50 ± 0.10 225.80 ± 2.48 0.0001**** 1 235.70 ± 4.45 237.10 ± 2.79 233.10 ± 3.60 225.90 ± 1.45 3 234.40 ± 4.54 238.00 ± 2.87 231.90 ± 3.36 226.50 ± 2.55 6 233.70 ± 4.54 239.30 ± 2.92 229.80 ± 3.32 227.20 ± 2.52 12 233.20 ± 4.38 240.50 ± 3.00 228.10 ± 3.15 228.30 ± 2.53 24 233.00 ± 4.41 241.60 ± 3.01 229.20 ± 3.23 230.00 ± 2.64 36 232.70 ± 4.53 240.40 ± 2.88 229.00 ± 3.25 231.40 ± 2.49 48 232.40 ± 4.53 241.50 ± 2.91 229.40 ± 3.46 234.70 ± 2.48 Mean values are higher in the male subgroups (P < 0.0001); Treatment and duration effects are not significant (P<0.12 and P<0.16, respectively); ****P<0.0001; other abbreviations are as used in table 2; (N=10 per subgroup)

Table 3: Effects of monotherapy with AML and HCZ on total cholesterol (mg/dl) in type 2 diabetic hypertensive subjects for 48-weeks.